326 related articles for article (PubMed ID: 20878125)
21. Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
Harada K; Itashiki Y; Takenawa T; Ueyama Y
Int J Oncol; 2010 Sep; 37(3):623-31. PubMed ID: 20664931
[TBL] [Abstract][Full Text] [Related]
22. [Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Yamada T; Masuda A; Tongu M; Hiraku O; Etou T; Sasaki K; Atsuda K; Morinaga S; Suzuki T; Suzuki Y; Osaku M; Miyagawa T; Asanuma F; Yamada Y
Gan To Kagaku Ryoho; 2006 Apr; 33(4):479-85. PubMed ID: 16612157
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
24. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
[TBL] [Abstract][Full Text] [Related]
26. S-1: a promising new oral fluoropyrimidine derivative.
Saif MW; Syrigos KN; Katirtzoglou NA
Expert Opin Investig Drugs; 2009 Mar; 18(3):335-48. PubMed ID: 19243284
[TBL] [Abstract][Full Text] [Related]
27. Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
Nakagawa T; Otsuki N; Masai Y; Sasaki R; Tsukuda M; Nibu K
Acta Otolaryngol; 2008 Aug; 128(8):936-40. PubMed ID: 18607998
[TBL] [Abstract][Full Text] [Related]
28. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
[TBL] [Abstract][Full Text] [Related]
29. Hyperthermia enhances the inhibition of tumor growth by 1-(2-tetrahydrofuryl)-5-fluorouracil/uracil (1:4) in tumors in mice and humans.
Emi Y; Kohnoe S; Yoshida M; Takahashi I; Maehara Y; Sugimachi K
Cancer; 1992 Sep; 70(5):1177-82. PubMed ID: 1515994
[TBL] [Abstract][Full Text] [Related]
30. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
32. An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Nishimura G; Yanoma S; Satake K; Ikeda Y; Taguchi T; Nakamura Y; Hirose F; Tsukuda M
Jpn J Cancer Res; 2000 Nov; 91(11):1199-203. PubMed ID: 11092987
[TBL] [Abstract][Full Text] [Related]
33. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Wada Y; Yoshida K; Suzuki T; Mizuiri H; Konishi K; Ukon K; Tanabe K; Sakata Y; Fukushima M
Int J Cancer; 2006 Aug; 119(4):783-91. PubMed ID: 16557585
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
36. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
37. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
38. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
39. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
40. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
